Search

Your search keyword '"Currier, Judith S"' showing total 96 results
Start Over Author "Currier, Judith S" Publisher lippincott williams & wilkins
96 results on '"Currier, Judith S"'

9. Impact of ART on Maternal Health After Cessation of Breastfeeding.

Author

Brummel, Sean S., Taha, Taha E., Angelidou, Konstantia (Nadia), Saidi, Friday, Atuhaire, Patience, Dula, Dingase, Moodley, Dhayendre, Matubu, Allen, Chareka, Gift, Nevrekar, Neetal, Vhembo, Tichaona, Fairlie, Lee, Theron, Gerhard, Mlay, Pendo, George, Kathleen, Basar, Michael, Chakhtoura, Nahida, Browning, Renee, Fowler, Mary Glenn, and Currier, Judith S.

Published
2021
Full Text
View/download PDF

14. Predictors of Viremia in Postpartum Women on Antiretroviral Therapy.

Author

Hoffman, Risa M., Warshaw, Meredith G., Amico, K. Rivet, Pilotto, Jose, Masheto, Gaerolwe, Achalapong, Jullapong, Machado, Elizabeth, Chokephaibulkit, Kulkanya, Duarte, Geraldo, João, Esau, Graham, Kathleen K., Knapp, Katherine M., Stek, Alice M., Scott, Gwendolyn B., Coletti, Anne, Loftis, Amy J., Chakhtoura, Nahida, and Currier, Judith S.

Published
2020
Full Text
View/download PDF

22. Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.

Author

Mathad, Jyoti S., Gupte, Nikhil, Balagopal, Ashwin, Asmuth, David, Hakim, James, Santos, Breno, Riviere, Cynthia, Hosseinipour, Mina, Sugandhavesa, Patcharaphan, Infante, Rosa, Pillay, Sandy, Cardoso, Sandra W., Mwelase, Noluthando, Pawar, Jyoti, Berendes, Sima, Kumarasamy, Nagalingeswaran, Andrade, Bruno B., Campbell, Thomas B., Currier, Judith S., and Cohn, Susan E.

Published
2016
Full Text
View/download PDF

27. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Author

Fowler, Mary G., Min Qin, Fiscus, Susan A., Currier, Judith S., Flynn, Patricia M., Chipato, Tsungai, McIntyre, James, Gnanashanmugam, Devasena, Siberry, George K., Coletti, Anne S., Taha, Taha E., Klingman, Karin L., Martinson, Francis E., Owor, Maxensia, Violari, Avy, Moodley, Dhayendre, Theron, Gerhard B., Bhosale, Ramesh, Bobat, Raziya, and Chi, Benjamin H.

Published
2017
Full Text
View/download PDF

38. Coronary Heart Disease in HIV-Infected Individuals.

Author

Currier, Judith S., Taylor, Anne, Boyd, Felicity, Dezii, Christopher M., Kawabata, Hugh, Burtcel, Beth, Jen-Fue Maa, and Hodder, Sally

Subjects
*CORONARY disease, *HIV-positive persons, *ANTIRETROVIRAL agents
Abstract

Compares the incidence of and relative risk for coronary heart disease (CHD) in HIV-infected individuals. Use of log linear regression analyses; Association of exposure to antiretroviral therapy and CHD incidence; Distribution of CHD diagnoses.

Published
2003
Full Text
View/download PDF

40. Cardiovascular Risk Associated With HIV Therapy.

Author

Currier, Judith S.

Subjects
*CARDIOVASCULAR diseases, *THERAPEUTICS, *HIV infections
Abstract

Investigates the cardiovascular risk associated with HIV therapy. Use of highly active antiretroviral therapy in treating patients with HIV; Assessment of dyslipidemia in HIV-infected individuals; Types of cardiovascular risk factors.

Published
2002
Full Text
View/download PDF

46. Introduction.

Author

Currier, Judith S.

Subjects
*AIDS, *RETROVIRUS disease treatment, *ATHEROSCLEROSIS, *CORONARY disease
Abstract

Presents a series of articles published in the September 1, 2002 supplement issue of the 'Journal of Acquired Immune Deficiency Syndromes.' Toxicities associated with highly active antiretroviral therapy (HAART); Use of HAART in HIV treatment; Impact of HIV infection on accelerated atherosclerosis and coronary heart disease.

Published
2002
Full Text
View/download PDF

48. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.

Author

McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, and Aberg JA

Subjects
Adult, CD4 Lymphocyte Count, Double-Blind Method, Female, HIV Infections complications, HIV Infections virology, HIV-Associated Lipodystrophy Syndrome chemically induced, HIV-Associated Lipodystrophy Syndrome virology, Humans, Male, Medication Adherence statistics & numerical data, Pilot Projects, Quality of Life, Viral Load, HIV Infections drug therapy, HIV-1, HIV-Associated Lipodystrophy Syndrome drug therapy, Uridine therapeutic use
Abstract

Background: Lipoatrophy is prevalent on thymidine nucleoside reverse transcriptase inhibitors (tNRTIs). A pilot trial showed that uridine (NucleomaxX) increased limb fat., Methods: A5229 was a multicenter trial in which HIV-infected individuals with lipoatrophy on tNRTI regimens were randomized to NucleomaxX or placebo. Primary endpoint was change in limb fat from baseline to week 48. The study was powered to detect 400-g difference between arms at week 48. A stratified Wilcoxon rank-sum test was used to assess between-arm differences., Results: The 165 participants were 91% men, 62% white; median age 49 years, CD4 cell count 506 cells/μl, and limb fat 3037 g; 81% had HIV-1 RNA 50 copies/ml or less; 76% were on zidovudine (ZDV). Baseline characteristics were similar between groups. Only 59% completed 48 weeks of treatment; however, only three participants (one on uridine) discontinued due to toxicity (diarrhea). In intent to treat, there was no difference for changes in limb fat between treatments at week 24 or week 48. On as-treated analysis, uridine resulted in an increase in %limb fat vs. placebo (3.4 vs. -0.8%, P = 0.01) at week 24 but not at week 48 (1.8 vs. 3.8%, P = 0.93). Similar results were seen when limiting the analysis to patients with at least 80% adherence. The results were not related to severity of lipoatrophy or type of tNRTI. No changes were found in facial anthropometrics, fasting lipids, trunk fat, CD4 cell count, or HIV RNA., Conclusions: We found a modest transient improvement in limb fat after 24 weeks of uridine. The lack of sustained efficacy at week 48 was not due to changes in adherence or reduction in sample size. Uridine was well tolerated and did not impair virologic control.

Published
2010
Full Text
View/download PDF

49. Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.

Author

Delaney JA, Scherzer R, Biggs ML, Shliplak MG, Polak JF, Currier JS, Kronmal RA, Wanke C, Bacchetti P, O'leary D, Tien PC, and Grunfeld C

Subjects
Adenine administration & dosage, Adenine adverse effects, Antiretroviral Therapy, Highly Active, Atherosclerosis pathology, Atherosclerosis virology, Female, HIV Infections complications, Humans, Male, Middle Aged, Organophosphonates administration & dosage, Risk Factors, Tenofovir, Adenine analogs & derivatives, Atherosclerosis chemically induced, HIV Infections drug therapy, HIV-1, Organophosphonates adverse effects, Tunica Intima pathology, Tunica Media pathology
Abstract

Background: Previous research has demonstrated an increase in carotid intima-media thickness (cIMT) in HIV-infected individuals compared to controls. However, the reason for this increased level of subclinical vascular disease is unknown., Objective: To identify HIV-related risk factors for increased cIMT., Methods: We evaluated the relationship between HIV-related characteristics (including markers of HIV disease severity and use of antiretroviral therapy) and cIMT measurements in the internal/bulb and common carotid regions among 538 HIV-infected participants from the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). We used Bayesian model averaging to estimate the posterior probability of candidate HIV and non-HIV-related risk factors being true predictors of increased cIMT. Variables with a posterior probability of more than 50% were used to develop a selected regression model for each of the anatomic regions., Results: For common cIMT, the Bayesian model selection process identified age, African-American race, and systolic and diastolic blood pressure with probability more than 95%, HDL cholesterol with probability 85% and Hispanic ethnicity with probability 51%. Among the HIV-related factors included in the analysis, only tenofovir use was selected (51% probability). In the selected model, duration of tenofovir use was associated with lower common cIMT (-0.0094 mm/year of use; 95% confidence interval: -0.0177 to -0.0010). For internal cIMT, no HIV-related risk factors were above the 50% posterior probability threshold., Conclusion: We observed an inverse association between duration of tenofovir use and common carotid cIMT. Whether this association is causal or due to confounding by indication needs further investigation.

Published
2010
Full Text
View/download PDF

50. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.

Author

Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, Tien PC, Shlipak MG, Sidney S, Polak JF, O'Leary D, Bacchetti P, and Kronmal RA

Subjects
Adult, Aged, Atherosclerosis pathology, Carotid Artery Diseases pathology, Carotid Artery, Common pathology, Carotid Artery, Internal pathology, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Risk Factors, Sex Factors, Smoking adverse effects, Tunica Intima pathology, Tunica Media pathology, Atherosclerosis virology, Carotid Artery Diseases virology, HIV Infections complications
Abstract

Background: Cardiovascular disease (CVD) is an increasing cause of morbidity and mortality in HIV-infected patients. However, it is controversial whether HIV infection contributes to accelerated atherosclerosis independent of traditional CVD risk factors., Methods: Cross-sectional study of HIV-infected participants and controls without pre-existing CVD from the study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) and the Multi-Ethnic Study of Atherosclerosis (MESA). Preclinical atherosclerosis was assessed by carotid intima-medial thickness (cIMT) measurements in the internal/bulb and common regions in HIV-infected participants and controls after adjusting for traditional CVD risk factors., Results: For internal carotid, mean IMT was 1.17 +/- 0.50 mm for HIV-infected participants and 1.06 +/- 0.58 mm for controls (P < 0.0001). After multivariable adjustment for demographic characteristics, the mean difference of HIV-infected participants vs. controls was 0.188 mm [95% confidence interval (CI) 0.113-0.263, P < 0.0001]. Further adjustment for traditional CVD risk factors modestly attenuated the HIV association (0.148 mm, 95% CI 0.072-0.224, P = 0.0001). For the common carotid, HIV infection was independently associated with greater IMT (0.033 mm, 95% CI 0.010-0.056, P = 0.005). The association of HIV infection with IMT was similar to that of smoking, which was also associated with greater IMT (internal 0.173 mm, common 0.020 mm)., Conclusion: Even after adjustment for traditional CVD risk factors, HIV infection was accompanied by more extensive atherosclerosis measured by IMT. The stronger association of HIV infection with IMT in the internal/bulb region compared with the common carotid may explain previous discrepancies in the literature. The association of HIV infection with IMT was similar to that of traditional CVD risk factors, such as smoking., (2009 Wolters Kluwer Health | Lippincott Williams & Wilkins)

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results